Skip to main content
. Author manuscript; available in PMC: 2018 Feb 4.
Published in final edited form as: Benef Microbes. 2017 Mar 27;8(2):207–215. doi: 10.3920/BM2016.0160

Figure 2.

Figure 2

(A) Concentration of chemokine (C-X-C motif) ligand 8 (CXCL8) in the nasal lavage by study day (geometric mean ± 95% CI). The concentration on the day of rhinovirus challenge (day 0) was significantly lower in the placebo group (P=0.04, ANCOVA). (B) Change in CXCL8 concentration from day 0 prior to virus challenge in volunteers treated with probiotic or placebo. The overall change from baseline was significantly greater in the placebo than in the probiotic group geometric mean ratio, probiotic:placebo=0.65, P=0.03, ANCOVA.